OrthoPediatrics (NASDAQ:KIDS – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
Analyst Ratings
This is a summary of recent recommendations and price targets for OrthoPediatrics and IceCure Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OrthoPediatrics | 0 | 1 | 2 | 0 | 2.67 |
| IceCure Medical | 0 | 0 | 2 | 0 | 3.00 |
OrthoPediatrics presently has a consensus target price of $40.00, suggesting a potential upside of 54.92%. IceCure Medical has a consensus target price of $2.70, suggesting a potential upside of 390.91%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than OrthoPediatrics.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OrthoPediatrics | $175.07 million | 3.51 | -$20.97 million | ($0.96) | -26.90 |
| IceCure Medical | $3.34 million | 7.52 | -$14.65 million | ($0.33) | -1.67 |
IceCure Medical has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OrthoPediatrics and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OrthoPediatrics | -14.35% | -5.44% | -4.67% |
| IceCure Medical | -410.22% | -111.27% | -81.41% |
Institutional and Insider Ownership
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
OrthoPediatrics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.
Summary
OrthoPediatrics beats IceCure Medical on 7 of the 13 factors compared between the two stocks.
About OrthoPediatrics
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
